Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
FACILITATE-HF is a multicenter, randomized, double-blind, placebo-controlled trial designed to determine whether initiation of finerenone during the early phase of hospitalization has beneficial effects in patients with AHF who have left ventricular ejection fraction 40% or more.
Eligibility Criteria
Patients eligible for inclusion in this study meet all of the following criteria: \<br\>Inclusion Criteria: 1. Patients ≥18 years of age, male or female\<br\> 2. Current hospitalization with AHF requiring intravenous loop diuretics or vasodilators during the index admission\<br\> 3. Patients have to have at least one of new or worsening symptoms due to HF and one of new or worsening physical examination findings due to HF \<br\> (i) symptom\<br\> dyspnoea, decreased exercise tolerance, or fatigue\<br\> (ii) physical examination\<br\> peripheral edema, increasing abdominal distention or ascites, pulmonary rales/crackles/crepitations, increased jugular venous pressure and/or hepatojugular reflux, S3 gallop, clinically significant or rapid weight gain\<br\> 4. Patients who are not hemodynamically unstable as defined by meeting the following criteria\<br\> 1. Systolic blood pressure ≥100 mmHg and no symptoms of hypotension within 6 hours prior to randomization\<br\> 2. No increase in intra